Adaptive Biotechnologies is a biotechnology business based in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.42 – a decrease of 20.79% over the previous week. Adaptive Biotechnologies employs 709 staff and has a trailing 12-month revenue of around $177.3 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.42 |
|---|---|
| 52-week range | $2.28 - $6.70 |
| 50-day moving average | $4.95 |
| 200-day moving average | $3.98 |
| Wall St. target price | $7.42 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.34 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.48 from 2024-11-19
| 1 week (2024-11-14) | -19.71% |
|---|---|
| 1 month (2024-10-21) | -1.54% |
| 3 months (2024-08-21) | -2.82% |
| 6 months (2024-05-21) | 28.37% |
| 1 year (2023-11-21) | 6.16% |
|---|---|
| 2 years (2022-11-21) | -45.76% |
| 3 years (2021-11-19) | 27.35 |
| 5 years (2019-11-21) | 27.86 |
| Revenue TTM | $177.3 million |
|---|---|
| Gross profit TTM | $-13,657,000 |
| Return on assets TTM | -16.37% |
| Return on equity TTM | -66.76% |
| Profit margin | -110.13% |
| Book value | $1.52 |
| Market Capitalization | $749.7 million |
TTM: trailing 12 months
We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as $2.28 up to $6.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 1.447. This would suggest that Adaptive Biotechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.